Contract facts
FederalNo full NAICS 325412 intel page yet. Browse NAICS intelligence
ORDER FOR IBUPROFEN TABLETS WITH NATIONAL CONTRACT WITH EXELAN PHARMACEUTICALS FOR REPACKAGING CONTRACT. is a federal award for Nac Pharmaceuticals (36E797) held by Exelan Pharmaceuticals Inc. Estimated value $165K ($165K obligated). Current period of performance ends Jul 31, 2023. Place of performance: BOCA RATON FL.
ORDER FOR IBUPROFEN TABLETS WITH NATIONAL CONTRACT WITH EXELAN PHARMACEUTICALS FOR REPACKAGING CONTRACT.
Recompete timing
PublicCurrent PoP ended Jul 31, 2023 (1117 days ago). The usual 12–18 month agency planning window is closed — recompete action looks late / overdue relative to a normal cycle. Watch for bridge orders, follow-ons, or a new solicitation.
Incumbent footprint
Public recordExelan Pharmaceuticals Inc — $184.3M obligated across 125 awards (firm-wide, all agencies) · lead buyer Department of Veterans Affairs (VA).
Related awards
Same parent · incumbentQuery this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Frequently asked questions
What is contract 36E79723N0029?
36E79723N0029 (ORDER for ibuprofen tablets WITH national) is a Nac Pharmaceuticals (36E797) award with a potential value of $165K, currently held by Exelan Pharmaceuticals Inc. Figures are USASpending-sourced public-record facts plus SCOUT recompete analysis.
What is 36E797-23-N-0029?
36E797-23-N-0029 is the dashed form of PIID 36E79723N0029 (ORDER for ibuprofen tablets WITH national), held by Exelan Pharmaceuticals Inc. Same award — SCOUT canonicalizes compact, dashed, and parent-child identifiers to one brief.
Which office awarded 36E79723N0029?
Nac Pharmaceuticals (36E797) awarded 36E79723N0029 to Exelan Pharmaceuticals Inc (potential $165K).
Who is the incumbent on 36E79723N0029?
Exelan Pharmaceuticals Inc is the incumbent with $184.3M across 125 related awards in SCOUT’s public footprint. The current period of performance ends Jul 31, 2023.
When does Exelan Pharmaceuticals Inc’s 36E79723N0029 come up for recompete?
SCOUT tracks a period-of-performance end of Jul 31, 2023. Actual solicitation timing can shift with extensions, bridges, or consolidations.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows.